D
Lyell Immunopharma, Inc. LYEL
$22.31 $1.507.21% NASDAQ
Recommendation
Prev Close
$20.81
Volume
53,712
Avg Vol (90D)
43,160
Market Cap
$441.55M
Dividend & Yield
--
52-Week Range
$7.65 - $25.20
P/E (TTM)
--
EPS (TTM)
-$22.26
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Lyell Immunopharma (LYEL, $22.1) RSI Indicator left the overbought zone on December 01, 2025
12/2/2025 - Tickeron - Stocks
Bank of America Securities Keeps Their Sell Rating on Lyell Immunopharma (LYEL)
12/1/2025 - TipRanks Financial Blog
Lyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week High - Here's What Happened
11/27/2025 - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week High - Here's What Happened
11/26/2025 - Ticker Report
Lyell Immunopharma (LYEL, $22.72) RSI Indicator left the overbought zone on November 24, 2025
11/25/2025 - Tickeron - Stocks
Lyell Immunopharma (LYEL) Sees Price Target Doubling by HC Wainwright LYEL Stock News
11/24/2025 - GuruFocus
Lyell Immunopharma price target raised by $10 at H.C. Wainwright, here's why
11/24/2025 - The Fly
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors must be happy
11/22/2025 - Simply Wall St
Lyell Immunopharma (LYEL, $19.13) entered Uptrend as Momentum indicator ascends above 0 level on Nov 21, 2025
11/22/2025 - Tickeron - Stocks
Lyell Immunopharma (LYEL, $19.13) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 21, 2025
11/22/2025 - Tickeron - Stocks
Lyell Immunopharma (LYEL, $19.13) price may drop as it broke higher Bollinger Band on Nov 21, 2025
11/22/2025 - Tickeron - Stocks
Lyell Immunopharma (LYEL, $17.43) entered Downtrend as Momentum indicator drops below 0 level on Nov 20, 2025
11/21/2025 - Tickeron - Stocks
Lyell Immunopharma (NASDAQ:LYEL) Posts Quarterly Earnings Results, Beats Expectations By $0.68 EPS
11/13/2025 - MarketBeat
Lyell Immunopharma reports Q3 revenue $15k vs $34k last year
11/12/2025 - The Fly
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
11/12/2025 - Globe Newswire
Lyell Immunopharma (LYEL, $17.68) entered Uptrend as Momentum indicator ascends above 0 level on Nov 10, 2025
11/11/2025 - Tickeron - Stocks
Lyell Immunopharma buys exclusive global rights to colorectal cancer drug
11/10/2025 - SeekingAlpha.com: All News
Lyell Immunopharma buys exclusive global rights to colorectal cancer drug
11/10/2025 - Seeking Alpha - Healthcare
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product ...
11/10/2025 - GuruFocus
Lyell Immunopharma acquires exclusive global rights to LYL273
11/10/2025 - The Fly
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
11/10/2025 - Globe Newswire
lyell signs 185m deal impressive phase 1 stage colorectal cancer car t
11/10/2025 - FierceBiotech.com - Biotech
Lyell Immunopharma (LYEL, $17.88) Stochastic Oscillator left the oversold zone on November 06, 2025
11/7/2025 - Tickeron - Stocks
Lyell Immunopharma (LYEL, $16.55) entered Downtrend as Momentum indicator drops below 0 level on Nov 03, 2025
11/4/2025 - Tickeron - Stocks
Lyell Immunopharma Appoints New Financial Leadership Team
11/3/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$41.00K
EBITDA (TTM)
-$184.20M
EBIT (TTM)
-$198.37M
Net Income (TTM)
-$325.66M
Balance Sheet
Total Assets (Q)
$407.97M
Total Debt (Q)
$44.29M
Total Liabilities (Q)
$78.84M
Book Value Per Share (Q)
$17.06
Cash Flow
Cash from Operations (TTM)
-$165.02M
Cash from Investing (TTM)
$138.97M
Cash from Financing (TTM)
$50.62M
Net Change in Cash (TTM)
$24.57M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
0.90
7-Day Total Return
16.62%
30-Day Total Return
28.81%
60-Day Total Return
69.66%
90-Day Total Return
62.49%
Year to Date Total Return
72.95%
1-Year Total Return
18.85%
2-Year Total Return
-41.29%
3-Year Total Return
-71.62%
5-Year Total Return
--
52-week Low
Jun 02, 2025 - $7.65
52-week High
Nov 28, 2025 - $25.20
Valuation
Market Cap
$441.55M - Small Cap
Enterprise Value
$166.21M
Price/Sales (TTM)
9,459.09
Price/Book (Q)
1.22
Dividends and Shares
Shares Outstanding
18.27
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.lyell.com
Phone Number
650 695 0677
Address
201 Haskins Way
South San Francisco, CA 94080
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed